Holli Cherevka - 21 May 2021 Form 4 Insider Report for Ampio Pharmaceuticals, Inc.

Role: CHIEF OPERATING OFFICER
Signature: /s/ Daniel Stokely, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 21 May 2021
Net transactions value: -$3,878
Form type: 4
Filing time: 25 May 2021, 15:45:25 UTC
Next filing: 13 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMPE	Common Stock	Options Exercise	$1,328	+2,603		$0.5100	2,603	21 May 2021	Direct	F1
transaction	AMPE	Common Stock	Sale	$5,206	-2,603	-100%	$2.00^*	0	21 May 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMPE	Stock Option (Right to Buy)	Options Exercise	$0	-2,603	-1.7%	$0.000000	152,766	21 May 2021	Common Stock	2,603	$0.5100	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 12, 2021.
F2	Options were granted and previously reported on a Form 4 filed on September 18, 2019, where 50% of the options awarded vested and became exercisable on the grant date of September 16, 2019 and the other 50% of the options awarded vested and became exercisable on the first anniversary of the grant date.